Trials / Completed
CompletedNCT03217331
CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Cardiora Pty. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b/IIa, single centre, non-randomised open-label uncontrolled study to assess safety, effect and PK of oral CRD-102 in patients with RHF associated with the presence of an LVAD.
Detailed description
The study will be conducted over a 40 day time period inclusive of screening and follow up time periods. Eligible subjects will receive oral CRD-102 for 14 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CRD-102 | 14 mg CRD-102 capsules administered twice daily orally for 14 days. |
Timeline
- Start date
- 2018-03-06
- Primary completion
- 2018-10-10
- Completion
- 2019-05-30
- First posted
- 2017-07-14
- Last updated
- 2019-06-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03217331. Inclusion in this directory is not an endorsement.